Abstract
The pediatric definition of the term dwarfism is applied to children whose height is 4 standard deviations or more (≥4 SD) below the mean of their coevals. Primary disturbances in growth regulation can be caused by a myriad of disease states. Intrinsic abnormalities of bone or cartilage as well as numerous systemic diseases affect growth (Table 26). The focus in this chapter
is on growth retardation caused by hyposomatotropism. Several terms used in the past, including primordial dwarfism, ateleotic dwarfism, genetic dwarfism, and constitutional dwarfism, have been mostly discarded currently, owing to the meaningless nature of such terms. It used to be believed that growth hormone (GH) deficiency represented a relatively uncommon (5–10%) cause of growth retardation. This belief was fostered in an era when GH deficiency was a relatively simple and straightforward entity (i.e., failure to grow was clearly a result of failure to generate GH by the anterior pituitary). In the short span of merely the past 10 years, GH-related growth disorders have come to be recognized as a heterogeneous group of disorders with diverse underlying mechanisms. Indeed, this entity is rapidly being elevated to the status of a fairly common etiology for growth retardation. Regardless of the frequency of occurrence, GH-related growth disorder may be the only group— besides hypothyroidism—in which some therapeutic rewards are attainable; a fact that is especially important, since delays in diagnosis can cost tremendous psychosocial maladjustments.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Wehrenberg WB, Brazeau P, Luben R, et al: Inhibition of the pulsatile secretion of growth hormone by monoclonal antibodies to hypothalamic growth hormone releasing factor. Endocrinology 111:2147, 1982.
Phillips LS, Vassilopoulou-Sellin R: Somatomedins. N Engl J Med 302:371, 1980.
Talwar GP, Pandian MR, Kumar N, et al: Mechanism of action of pituitary growth hormone. Recent Prog Horm Res 31:141, 1975.
Phillips LS, Fusco AC, Unterman TG: Nutrition and somatomedin. XIV. Altered levels of somatomedins and somatomedin inhibitors in rats with streptozotocin-induced diabetes. Metabolism 34:765, 1985.
Phillips LS, Orawski AT, Belosky DC: Somatomedin and nutrition. IV. Regulation of somatomedin activity and growth cartilage activity by quantity and composition of diet in rats. Endocrinology 103:121, 1978.
Phillips LS, Orawski AT: Nutrition and somatomedin. III. Diabetic control, somatomedin, and growth in rats. Diabetes 26:864, 1977.
Pugliese MT, Lifshitz F, Grad G, et al: Fear of obesity: A cause of short stature and delayed puberty. N Engl J Med 309:513, 1983.
Lucas AR: Undernutrition and growth. (Editorial.) N Engl J Med 309:550, 1983.
Laron Z, Keret R, Bauman B, et al: Differential diagnosis between hypothalamic and pituitary hGH deficiency with the aid of synthetic GH-RH 1-44.Clin Endocrinol (Oxf) 21:9, 1984.
Yalow RS, Hall K, Luft R: Radioimmunoassay of somatomedin B: Application to clinical and physiologic studies. J Clin Invest 55:127, 1975.
Schalch DS, Heinrich UE, Koch JG, et al: Non-suppressible insulin-like activity (NSILA). I. Development of a new sensitive competitive protein-binding assay for determination of serum levels. J Clin Endocrinol Metabl 46:664, 1978.
Furlanetto RW, Underwood LE, Van Wyk JJ, et al: Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 60:648, 1977.
Miller WL, Eberhardt NL, Baxter JD: Growth hormone genes. In Black PM, Zervas NT, Ridgeway EC, et al (eds): Secretory Tumors of the Pituitary Gland. Progress in Endocrine Research and Therapy. Vol. 1. Raven, New York, 1984, p. 135.
Guillemin R, Brazeau P, Böhlen P, et al: Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218:585, 1982.
Rivier J, Spiess J, Thorner M, et al: Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature (Lond) 300:276, 1982.
Thorner MO, Rivier J, Spiess J, et al: Human pancreatic growth-hormone releasing factor selectively stimulates growth-hormone secretion in man. Lancet 1:24, 1983.
Gelato MC, Pescovits O, Cassorla F, et al: Effects of a growth hormone releasing factor in man. J Clin Endocrinol Metab 57:674, 1983.
Rosenthal SM, Schriock EA, Kaplan SL, et al: Synthetic human pancreatic growth hormone-releasing factor stimulates growth hormone secretion in normal man. J Clin Endocrinol Metab 57:677, 1983.
Borges JLC, Blizzard RM, Gelato MC, et al: Effects of human pancreatic tumour growth hormone releasing factor on growth hormone and somatomedin-C levels in patients with idiopathic growth hormone deficiency. Lancet 2:119, 1983.
Grossman A, Savage MO, Wass JAH: Growth-hormone-releasing factor in growth hormone deficiency: Demonstration of a hypothalamic defect in growth hormone release. Lancet 2:137, 1983.
Borges JLC, Blizzard RM, Evans WS, et al: Stimulation of growth hormone (GH) and somatomedin-C in idiopathic GH-deficient subjects by intermittent pulsatile administration of synthetic human pancreatic tumor GH-releasing factor. J Clin Endocrinol Metab 59:1, 1984.
Schechter J, Kovacs K, Rimoin D: Isolated growth hormone deficiency: Immunocytochemistry. J Clin Endocrinol Metab 59:798, 1984.
Rogol AD, Blizzard RM, Johanson AJ, et al: Growth hormone release in response to human pancreatic tumor growth hormone-releasing hormone-40 children with short stature. J Clin Endocrinol Metab 59:580, 1984.
Gelato MC, Ross JL, Malozowski S, et al: Effects of pulsatile administration of growth hormone (GH)-releasing hormone on short term linear growth in children with GH deficiency. J Clin Endocrinol Metab 61:444, 1985.
Thorner MO, Reschke J, Chitwood J, et al: Acceleration of growth in two children treated with human growth hormone-releasing factor. N Engl J Med 312:4, 1985.
Phillips JA III: Genetic diagnosis: Differentiating growth disorders. Hosp Pract 20:85, 1985.
Phillips JA III, Hjelle BL, Seeberg PH, et al: A molecular basis for familial isolated growth hormone deficiency. Proc Natl Acad Sci USA 78:6372, 1981.
Phillips JA III: The molecular basis of familial growth hormone deficiency. In Messer A, Porter IH (eds): Recombinant DNA and Medical Genetics. Academic, New York, 1983, p. 9.
Phillips JA III, Parks JS, Hjelle BL, et al: Genetic analysis of familial isolated growth hormone deficiency Type I. J Clin Invest 70:489, 1982.
Spiliotis BE, August GP, Hung W, et al: Growth hormone neurosecretory dysfunction: A treatable cause of short stature. JAMA 251:2223, 1984.
Kowarski AA, Schneider J, Ben-Galim E, et al: Growth failure with normal serum RIA-GH and low somatomedin activity: Somatomedin restoration and growth acceleration after exogenous GH. J Clin Endocrinol Metab 47:461, 1978.
Hayek A, Peake GT: Growth and somatomedin-C responses to growth hormone in dwarfed children. J Pediatr 99:868, 1981.
Frazer T, Gavin JR, Daughaday WH, et al: Growth hormone-dependent growth failure. J Pediatr 101:12, 1982.
Rudman D, Kutner MH, Blackston RD, et al: Normal variant short stature: Subclassification based on responses to exogenous human growth hormone. J Clin Endocrinol Metab 49:92, 1979.
Rudman D, Kutner MH, Goldsmith MA, et al: Further observations on four subgroups of normal variant short stature. J Clin Endocrinol Metab 51:1378, 1980.
Rudman D, Kutner MH, Blackston RD, et al: Children with normal-variant short stature: Treatment with human growth hormone for six months. N Engl J Med 305:123, 1981.
Preece, MA: A new task for human growth hormone? Br Med J 283:1145, 1981.
Van Vliet G, Styne DM, Kaplan SL, et al: Growth hormone treatment for short stature. N Engl J Med 309:1016, 1983.
Friesen HG: Raben lecture: a tale of stature. Endocr Rev 1:309, 1980.
Valenta LJ, Sigel MB, Lesniak MA, et al: Pituitary dwarfism in a patient with circulating abnormal growth hormone polymers. N Engl] Med 312:214, 1985.
Gorden P, Hendricks CM, Roth J: Evidence for “big” and “little” components of human plasma and pituitary growth hormone. J Clin Endocrinol Metab 36:178, 1973.
Abucham-Filho JZ, Czepielewski MA, Ribeiro SRR, et al: Abnormal growth hormone and dwarfism. TV Engl J Med 313:268, 1985.
Laron Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentration of growth hormone-A new inborn error of metabolism? Israel] Med Sci 2:152, 1966.
Laron Z, Pertzelan A, Karp M: Pituitary dwarfism with high serum levels of growth hormone. Israel J Med Sci 4:883, 1968.
Laron Z, Pertzelan A, Karp M, et al: Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone: Measurement of sulfation factor, metabolic and linear growth responses. J Clin Endocrinol 33:332, 1971.
Laron Z, Kowadlo-Silbergeld A, Eshet R, et al: Growth hormone resistance. Ann Clin Res 12:269, 1980.
Merimee TJ, Rimoin DL, Rabinowitz D, et al: Metabolic studies in the African pygmy. Trans Assoc Am Physicians 81:221, 1968.
Merimee TJ, Rimoin DL, Cavalli-Sforza LL: Metabolic studies in the African pygmy. J Clin Invest 51:395, 1972.
Rimoin DL, Merimee TJ, McKusick VA: Growth-hormone deficiency in man: An isolated, recessively inherited defect. Science 152:1635, 1966.
Merimee TJ, Zapf J, Froesch ER: Dwarfism in the pygmy: An isolated deficiency of insulinlike growth Factor I. N Engl J Med 305:965, 1981.
Rosenfeld RG, Hintz RL: Diagnosis and management of growth disorders. Drug Therapy 13:61, 1983.
Rosenfeld RG: Evaluation of growth and maturation in adolescence. Pediatr Rev 4:175, 1982.
Post EM, Richman RA: A condensed table for predicting adult stature. J Pediatr 98:440, 1981.
Blethen SL, Chasalow FI: Use of a two-site immunoradiometric assay for growth hormone (GH) in identifying children with GH-dependent growth failure. J Clin Endocrinol Metabl 57:1031, 1983.
Frisch H, Herkner K, Schober E, et al: Prolactin and thyrotrophin response to thyrotrophin-releasing hormone in growth hormone deficiency. Arch Dis Child 57:769, 1982.
Bucher H, Zapf J, Torresani T, et al: Insulin-like growth factors I and II, prolactin, and insulin in 19 growth hormone-deficient children with excessive, normal, or decreased longitudinal growth after operation for craniopharyngioma. N Engl J Med 309:1142, 1983.
Powell GF, Brasel J A, Blizzard RM: Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. N Engl J Med 276:1271, 1967.
Powell GF, Brasel JA, Raid S, et al: Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. II. Endocrinologic evaluation of the syndrome. N Engl J Med 276:1279, 1967.
Raben MS: Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 18:901, 1958.
Tanner JM, Whitehouse RH, Hughes PCR, et al: Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children, with growth hormone deficiency, low birthweight, inherited smallness, Turner’s syndrome and other complaints. Arch Dis Child 46:745, 1971.
Preece MA, Tanner JM, Whitehouse RH, et al: Dose dependence of growth response to human growth hormone in growth hormone deficiency. J Clin Endocrinol Metab 42:477, 1976.
Milner RDG, Russell-Fraser T, Brook CGD, et al: Experience with human growth hormone in Great Britain: The report of the MRC working party. Clin Endocrinol 11:15, 1979.
Aceto T, Frasier SD, Hayles AB, et al: Collaborative study of the effects of human growth hormone in growth hormone deficiency. I. First year of therapy. J Clin Endocrinol Metab 35:483, 1972.
Frasier SD: Human pituitary growth hormone(hGH) therapy in growth hormone deficiency. Endocr Rev 4:155, 1983.
Seip M, Trygstad O: Experiences with human growth hormone in pituitary dwarfism. Acta Paediatr Scand 55:287, 1966.
Frasier SD, Aceto T, Hayles AB: Collaborative study of the effects of human growth hormone in growth hormone deficiency. V. Treatment with growth hormone administered once a week. J Clin Endocrinol Metab 47:686, 1978.
Ferrandez A, Zachmann M, Prader A, et al: Isolated growth hormone deficiency in prepubertal children. Influence of human growth hormone on longitudinal growth, adipose tissue, bone mass and bone maturation. Helv Paediatr Acta 25:566, 1970.
Dean HJ, Kellett JG, Bala RM, et al: The effect of growth hormone treatment on somatomedin levels in growth hormone-deficient children. J Clin Endocrinol Metab 55:1167, 1982.
Rosenfeld RG, Kemp SF, Hintz RL: Constancy of somatomedin response to growth hormone treatment of hypopituitary dwarfism, and lack of correlation with growth rate. J Clin Endocrinol Metab 53:611, 1981.
Preece MA, Tanner JM: Results of intermittent treatment of growth hormone deficiency with human growth hormone. J Clin Endocrinol Metab 45:169, 1977.
Lippe B, Frasier SD, Kaplan SA: Use of growth hormone-gel. Arch Dis Child 54:609, 1979.
MacGillivray MH, Kolotkin M, Munschauer RW: Enhanced linear growth responses in hypopituitary dwarfs treated with growth hormone plus androgen versus growth hormone alone. Pediatr Res 8:103, 1974.
Parker ML: Antibody production in patients receiving human growth hormone and possible therapeutic implications. In: Report of the Fifty-fourth Ross Conference on Pediatric Research, Baltimore, MD, March 1965 ,p. 49.
Kaplan SL, Savage DCL, Suter S, et al: Antibodies to human growth hormone arising in patients treated with human growth hormone: Incidence, characteristics, and effects on growth. In: Advances in Human Growth Hormone Research; A Symposium. U.S. Department of Health, Education and Welfare, Publication No. NIH 74-612, 725, 1973.
Rosenbloom AL, Riley WJ, Silverstein JH, et al: Low dose single weekly injections of growth hormone: Response during first year of therapy of hypopituitarism. Pediatrics 66:272, 1980.
Root AW, Bongiovanni AM, Eberlein WR: Diagnosis and management of growth retardation with special reference to the problem of hypopituitarism. J Pediatr 78:737, 1971.
Lippe BM, Van Herle AJ, LaFranchi SH, et al: Reversible hypothyroidism in growth hormone-deficient children treated with human growth hormone. J Clin Endocrinol Metab 40:612, 1975.
Rubio GR, Mellinger C, Zafar MS, et al: Evaluation of thyroid function during growth hormone therapy. Metabolism 25:15 ,1976.
Cacciari E, Cicognani A, Pirazzoli P, et al: Effect of long-term GH administration on pituitary-thyroid function in idiopathic hypopituitarism. Acta Paediatr Scand 68:405, 1979.
Brown P, Gajdusek DC, Gibbs CJ Jr, et al: Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med 313:728, 1985.
Fatal degenerative neurologic disease in patients who received pituitary-derived human growth hormone. MMWR 34:359, 1985.
Powell-Jackson J, Weller RO, Kennedy P, et al: Creutzfeld-Jakob disease following human growth hormone administration. Lancet 2:244, 1985.
Koch TK, Berg BO, De Armond SJ, et al: Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism: Possible relation to the administration of cadaveric human growth hormone. N Engl J Med 313:731, 1985.
Gibbs CJ Jr, Joy A, Heffner R, et al: Clinical and pathological features and laboratory confirmation of Creutzfeld-Jakob disease in a recipient of pituitary-derived human growth hormone. N Engl J Med 313:734, 1985.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Publishing Corporation
About this chapter
Cite this chapter
Kannan, C.R. (1987). Hypopituitary Dwarfism. In: The Pituitary Gland. Clinical Surveys in Endocrinology, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1849-1_4
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1849-1_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9032-2
Online ISBN: 978-1-4613-1849-1
eBook Packages: Springer Book Archive